Company: XAIR
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021561
Chunk: 36

Company: Beyond Air, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Part I, Item 1
Chunk 36
---
    $(2,632) 
    $(1,517) 
    $(16,336)
  
    Operating activities included in net loss: 

    Depreciation and amortization 
    $1,605  
    $20  
    $-  
    $1,625 
  
    Stock-based compensation expense 
    $2,175  
    $1,033  
    $144  
    $3,352 

    Cash used in operations 
    $(7,228) 
    $(712) 
    $(1,039) 
    $(8,979)
  
    Cash from (used in) investing 
     (31) 
     847  
     -  
     816 
  
    Cash from financing 
     12,484  
     -  
     500  
     12,984 
  
    Impact of exchange rates 
     159  
     34  
     (48) 
     145 
  
    Net change for the period 
    $5,384  
    $169  
    $(587) 
    $4,966 

The
following table summarizes financial performance by business segment for the three months ended September 30, 2024:

    (in thousands) 
    Beyond Air  
    Beyond Cancer  
    NeuroNos  
    Total 
  
    Capital expenditures 
    $1,173  
    $2  
    $          -  
    $1,175 

    Revenues 
    $798  
    $-  
    $-  
    $798 
  
    Cost of revenues 
     (1,882) 
     -  
     -  
     (1,882)
  
    Research and development 
     (3,432) 
     (1,153) 
     -  
     (4,585)
  
    Selling, general, and administrative 
     (4,826) 
     (2,337) 
     -  
     (7,163)
  
    Loss from operations 
     (9,342) 
     (3,490) 
     -  
     (12,833)
  
    Interest and finance expense 
     (927) 
     -  
     -  
     (927)